CLAIM AMENDMENTS

1. – 39. (canceled)

40. (currently amended) A compound of formula A or formula B:



(A)



(B)

where

R^1, R^2, and R^3 are independently, hydrogen, or optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substitutedheterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), $-CF_3$, halogen, nitro, -CN, $-OR^9$, $-SR^9$, $-NR^9R^{10}$, $-NR^9$(carboxy(lower alkyl)), $-C(=O)R^9$, $-C(=O)OR^9$, $-C(=O)NR^9R^{10}$, $-OC(=O)R^9$, $-SO_2R^9$, $-OSO_2R^9$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{10}$ or $-NR^9C(=O)R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-$N(C_{1-2}$ alkyl$)_2$, lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl(lower alkyl), aryl(lower alkyl), optionally substituted aryl, optionally substituted aryloxy, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C_{1-2} alkyl) group,

R^4 and R^5 are independently, ~~hydrogen,~~ hydrogen or lower alkyl ~~optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted aryl(lower alkyl), or, together, are $(CH_2)_{2-4}$-~~,

R^6 is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted

PAGE 5/14 * RCVD AT 5/3/2005 2:12:38 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID: * DURATION (mm-ss):04-18

heteroaryl(lower alkyl), $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-SO_2R^{11}$, or $-SO_2NR^{11}R^{12}$,where R^{11} and R^{12} are independently, hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), aryl, optionally substituted aryloxy, heteroaryl, heteroaryl(lower alkyl), or R^{11} and R^{12} together are $-(CH_2)_{4-6}-$,

or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers thereof.

41. (previously presented) The compound of claim 40, where said compound is a compound of Formula A or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers thereof.

42. (previously presented) The compound of claim 40, where said compound is a compound of Formula B or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers thereof.

43. (previously presented) The compound of claim 40, where R^1 is hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen, $-OR^9$, $-NR^9R^{10}$, $-C(=O)OR^9$, $-C(=O)NR^9R^{10}$, $-SO_2NR^9R^{10}$, or $-NR^9C(=O)R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-$N(C_{1-2}$ alkyl$)_2$, lower alkyl(optionally substituted heterocycloalkyl), aryl(lower alkyl), optionally substituted aryl, heteroaryl, or heteroaryl(lower alkyl).

44. (previously presented) The compound of claim 43, where R^1 is optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen, $-OR^9$, $-NR^9R^{10}$, $-C(=O)OR^9$, $-C(=O)NR^9R^{10}$, $-SO_2NR^9R^{10}$, or $-NR^9C(=O)R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-$N(C_{1-2}$ alkyl$)_2$, lower alkyl(optionally substituted heterocycloalkyl), aryl(lower alkyl), optionally substituted aryl, heteroaryl, or heteroaryl(lower alkyl).

45. (previously presented) The compound of claim 40, where R^2 is hydrogen, optionally substituted lower alkyl, cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted

PAGE 6/14 * RCVD AT 5/3/2005 2:12:38 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID: * DURATION (mm-ss):04-18

aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen,-OR^9, -NR^9(carboxy(lower alkyl)), -$C(=O)OR^9$, -$C(=O)NR^9R^{10}$, -$SO_2NR^9R^{10}$, or -$NR^9C(=O)R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-$N(C_{1-2}$ alkyl$)_2$, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted aryloxy, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are -$(CH_2)_{4-6}$- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C_{1-2} alkyl) group.

46. (previously presented) The compound of claim 45, where R^2 is optionally substituted lower alkyl, cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen, -OR^9, -NR^9(carboxy(lower alkyl)), -$C(=O)OR^9$, -$C(=O)NR^9R^{10}$, -$SO_2NR^9R^{10}$, or -$NR^9C(=O)R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-$N(C_{1-2}$ alkyl$)_2$, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted aryloxy, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are -$(CH_2)_{4-6}$- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C_{1-2} alkyl) group.

47. (previously presented) The compound of claim 40, where R^3 is hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), halogen, -OR^9, -NR^9R^{10}, -$C(=O)OR^9$, or -$C(=O)NR^9R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-$N(C_{1-2}$ alkyl$)_2$, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted aryloxy, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are -$(CH_2)_{4-6}$- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C_{1-2} alkyl) group.

48. (previously presented) The compound of claim 47, where R^3 is optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally

PAGE 7/14 * RCVD AT 5/3/2005 2:12:38 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID: * DURATION (mm-ss):04-18

substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), halogen, $-OR^9$, $-NR^9R^{10}$, $-C(=O)OR^9$, or $-C(=O)NR^9R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-$N(C_{1-2}$ alkyl$)_2$, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted aryloxy, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C_{1-2} alkyl) group.

49. (canceled)

50. (previously presented) The compound of claim 40, where R^6 is hydrogen, optionally substituted lower alkyl, alkenyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-SO_2R^{11}$, or $-SO_2NR^{11}R^{12}$, where R^{11} and R^{12} are independently, hydrogen, optionally substituted lower alkyl, cycloalkyl, cycloalkyl(lower alkyl), aryl heteroaryl, heteroaryl(lower alkyl), or R^{11} and R^{12} together are $-(CH_2)_{4-6}-$.

51. (previously presented) The compound of claim 40 that is a compound of formula Aa or formula Ba:



(Aa)



(Ba)

where:

R^1, R^2, R^3, R^4, and R^5 are as defined in claim 40,

R^{13} is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), $-CF_3$, halogen, nitro, -CN, $-OR^{15}$, $-SR^{15}$, $-NR^{15}R^{16}$, $-C(=O)R^{15}$,

PAGE 8/14 * RCVD AT 5/3/2005 2:12:38 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID: * DURATION (mm-ss):04-18

$-C(=O)OR^{15}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)R^{15}$, $-SO_2R^{15}$, $-SO_2NR^{15}R^{16}$, $-NR^{15}SO_2R^{16}$ or $-NR^{15}C(=O)R^{16}$, where R^{15} and R^{16} are independently, hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, $-CF_3$, cycloalkyl, optionally substituted heterocycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), or, together, are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH or N-(C_{1-2} alkyl) group,

each R^{14} is independently selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, hydroxy, halogen, $-CF_3$, $-OR^{17}$, $-NR^{17}R^{18}$, $-C(=O)R^{18}$, $-C(=O)OR^{18}$, $-C(=O)NR^{17}R^{18}$, where R^{17} and R^{18} are independently, hydrogen, lower alkyl, alkenyl, alkynyl, $-CF_3$, optionally substituted heterocycloalkyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted aryloxy, heteroaryl, heteroaryl(lower alkyl), or, together, are $-(CH_2)_{4-6}-$, optionally interrupted by one O, S, NH or N-(C_{1-2} alkyl) group, and

where n is an integer of 0 to 4,

or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers.

52. (previously presented) The compound of claim 51, where said compound is a compound of Formula Aa or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers.

53. (previously presented) The compound of claim 51, where said compound is a compound of Formula Ba or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers.

54. (previously presented) The compound of claim 51, where R^{13} is $-OR^{15}$, and R^{15} is hydrogen, lower alkyl optionally substituted with $-C(=O)OR^{19}$, where R^{19} is hydrogen or lower alkyl, alkenyl, alkynyl, $-CF_3$, cycloalkyl, optionally substituted heterocycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heteroaryl(lower alkyl).

55. (previously presented) The compound of claim 51, where R^{13} is hydrogen, optionally substituted lower alkyl, alkenyl, heterocycloalkyl, optionally substituted aryl, optionally

PAGE 9/14 * RCVD AT 5/3/2005 2:12:38 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID: * DURATION (mm-ss):04-18

substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), $-CF_3$, halogen, nitro, -CN, $-OR^{15}$, $-SR^{15}$, $-NR^{15}R^{16}$, $-C(=O)R^{15}$, $-C(=O)OR^{15}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)R^{15}$, $-SO_2R^{15}$, $-SO_2NR^{15}R^{16}$, or $-NR^{15}C(=O)R^{16}$, where R^{15} and R^{16} are independently, hydrogen, optionally substituted lower alkyl, alkenyl, cycloalkyl, optionally substituted heterocycloalkyl,cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl) or, together, are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH or N-(C_{1-2} alkyl) group.

56. (previously presented) The compound of claim 55, where R^{13} is optionally substituted lower alkyl, alkenyl, heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), $-CF_3$, halogen, nitro, -CN, $-OR^{15}$, $-SR^{15}$, $-NR^{15}R^{16}$, $-C(=O)R^{15}$, $-C(=O)OR^{15}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)R^{15}$, $-SO_2R^{15}$, $-SO_2NR^{15}R^{16}$, or $-NR^{15}C(=O)R^{16}$, where R^{15} and R^{16} are independently, hydrogen, optionally substituted lower alkyl, alkenyl, cydoalkyl, optionally substituted heterocycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl) or, together, are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH or N-(C_{1-2} alkyl) group.

57. (previously presented) The compound of claim 51, where R^{14} is independently selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, hydroxy, halogen, $-CF_3$, $-OR^{17}$ $-NR^{17}R^{18}$, $-C(=O)R^{18}$, $-C(=O)OR^{18}$, $-C(=O)NR^{17}R^{18}$, where R^{17} and R^{18} are, independently, hydrogen, lower alkyl, alkenyl, or optionally substituted aryl.

58. (previously presented) The compound of claim 56, where n is an integer of 1 to 2.

59. (previously presented) The compound of claim 58, where n is 1.

60. (previously presented) The compound of claim 51, where R^1 is lower alkyl.

61. (previously presented) The compound of claim 51, where R^2 and R^3 are independently selected from hydrogen, lower alkyl, halogen, OR^9, $-NR^9R^{10}$, where R^9 and R^{10} are independently lower alkyl, substituted lower alkyl, or substituted aryl, or R^9 and R^{10} together are $-(CH_2)_{4-6}-$

PAGE 10/14 * RCVD AT 5/3/2005 2:12:38 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID: * DURATION (mm-ss):04-18

optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C_{1-2} alkyl) group.

62. (previously presented) The compound of claim 56, where R^{13} is independently selected from halogen, optionally substituted aryl, $-CF_3$, $-CH_3$, -CN, $-OR^{15}$, $-C(=O)R^{15}$, $-C(=O)OR^{15}$, $-C(=O)NR^{15}R^{16}$, or $-CO_2H$.

63. (previously presented) The compound of claim 51, where R^{14} is independently selected from halogen, optionally substituted lower alkyl, $-CF_3$, $-OR^{17}$, aryl, heteroaryl, $-NR^{17}R^{18}$, $-C(=O)R^{17}$, $-C(=O)OR^{17}$, $-C(=O)NR^{17}R^{18}$, or $-CO_2H$, where R^{17} and R^{18} are, independently, lower alkyl, substituted lower alkyl, or substituted aryl, or, together, are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH or N-(C_{1-2} alkyl) group.

64. (previously presented) The compound of claim 51, where R^2 is 4-methylpiperazinyl, R^{13} is 3-CF_3, and R^{14} is 4-F.

65. (previously presented) A pharmaceutical composition comprising:

(a) a therapeutically effective amount of a compound of claim 40; and

(b) a pharmaceutically acceptable excipient.

66. (canceled)

67. (currently amended) A method of treating an allergic, inflammatory, or autoimmune disorder or disease selected from the group consisting of asthma, atherosclerosis, glomerulonephritis, pancreatitis, restenosis, rheumatoid arthritis, diabetic nephropathy, pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, transplant rejection, and multiple sclerosis, comprising administering a therapeutically effective dose of at least one compound of claim 40 to a mammal in need of such treatment.

68. (canceled)

69. (canceled)

70. (canceled)

71. (canceled)

PAGE 11/14 * RCVD AT 5/3/2005 2:12:38 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID: * DURATION (mm-ss):04-18